Pressure BioSciences (OTCQB: PBIO) (“PBI”) earlier this month announced potentially ground-breaking results from a consumer focus group testing a THC oral spray developed using the company’s innovative UltraShear(TM) nanoemulsification platform. The spray demonstrated strong potency and extremely fast absorption that could put it on track to become a best-in-class cannabis product in terms of speed to effects, stability and bioavailability. Pressure BioSciences is developing the THC oral spray tested in the consumer focus group in partnership with California-based cannabis manufacturer, Crème De Canna. This comes on the heels of the company’s December announcement of its first commercial shipment of a CBD oral spray manufactured with the same UltraShear technology. The $75,000 shipment to Safer Medical of Montana is the first of many that PBI expects to make in 2023 to distributors of CBD products throughout the U.S. In recent announcements, PBIO has projected that CBD products manufactured using its patented UltraShear platform could potentially yield many millions in revenue before the end of its 2023 fiscal year.
To view the full press release, visit https://ibn.fm/xRjzK
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Pressure BioSciences’ primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) patented technology from BaroFold Inc. (the BaroFold technology) that allows entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based UltraShear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork